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Summary Cancer antigen 125 (CA 125) and cancer-associated serum antigen (CASA) were measured in 24 women with pelvic masses before
and after a gynaecological examination and ultrasonography. CA 125 decreased median 16% after manipulation (P < 0.0001) and CASA
decreased median 8% (P = 0.0077). The decline was found in patients with benign tumours as well as in patients with malignant tumours.
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Tumour markers are widely used in the diagnosis, monitoring and
follow-up ofovarian cancer and serum is often drawn in relation to
a gynaecological examination and ultrasonography. In order to
evaluate the influence of these procedures on the tumour marker
level we measured cancer antigen 125 (CA 125) and cancer-
associated serum antigen (CASA) in patients with benign and
malignant pelvic masses before and after a gynaecological
examination combined with ultrasonography.
MATERIAL AND METHODS
We investigated 24 women with pelvic masses who underwent
laparotomy at the Department of Obstetrics and Gynaecology,
Odense University Hospital. The first blood sample was drawn
6-8 h before a preoperative gynaecological examination and
abdominal and transvaginal sonography. The second blood sample
was drawn 16-18 hours after the examinations and before the
operation. Serum was stored at -80°C within I h after sampling.
CA 125 and CASA were measured in duplicate by enzyme
immunoassays as described previously (Kierkegaard et al, 1995).
The specimens from each patient were measured simultaneously
with the same kit. The detection limit of CA 125 was 0.5 U ml-'
and the overall imprecision of the assay was 5.0-8.2 U ml-'
(Mogensen and Mogensen, 1995). The results were statistically
evaluated by Wilcoxon's matched-pairs test. When the CASA
level was outside the detection limit of 2.0-64.0 U ml the values
were considered unchanged.
RESULTS
The findings in the 24 patients with pelvic masses are described in
Table 1. CA 125 was unchanged in one patient with an endome-
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trial cyst and decreased in the remaining 23 patients. The decrease
was median 16% (range 0-50%, P < 0.0001). In the subgroup of
patients with malignant tumours the decrease was median 11I%
(range 8-25%, P = 0.018) and in patients with benign tumours
median 18% (range 0-50%, P = 0.0003).
Only nine patients had CASA levels within the detection limit
and the median decrease was 8% (range 4-50%, P = 0.0077).
No patients classified as true positive turned out to be false
negative after manipulation using the most common thresholds of
CA 125 (35, 20 or 15 U ml-') and CASA (8, 6 or 4 U ml-'). With a
CA 125 threshold of 20 or 15 U ml-' the patient with a fibroma
changed from false positive to true negative (Table 1). Similarly, a
patient with a simple cyst changed from false positive to true nega-
tive using the CASA threshold of4 U ml'.
DISCUSSION
In the present paper we have evaluated the effect of a gynaecolog-
ical examination and ultrasonography on serum levels of CA 125
and CASA. An increased marker level - true or false - may
involve extensive investigations and certainly worries the patient.
On the other hand, a false-negative result may delay treatment and
may result in decreased quality oflife and survival. Therefore, it is
important to look for conditions other than the malignant disease
that may influence the tumour marker level in serum.
Abdominal surgery may cause an increase in CA 125 irrespec-
tive of whether the diagnosis of the patient was ovarian cancer,
cervical cancer or atherosclerotic disease with aortic surgery; CA
125 reaches its maximum during the second postoperative week
(Van der Zee et al, 1990; Mogensen et al, 1993). This non-specific
increase may be explained by a traumatically induced inflamma-
tion of the peritoneum. Healthy women may have moderately
increased CA 125 values during menstruation (Lehtovirta et al,
1990), which may be due to antigen leakage from endometrial
glands into the circulation. Increased marker levels have also been
found during the first trimester of pregnancy (Kobayashi et al,
1989) and this finding may be caused by CA 125 leakage from the
decidual cells and the amniotic fluid into the circulation.
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Table 1 CA 125 and CASA before and after tumour manipulation in 24 patients with pelvic masses
Histology FIGO stage CA 125 CASA
Before After Differencea Before After Differenceb
U ml-' U ml-1 U ml-1 (%) U ml-' U ml-1 U ml-1 (%)
Malignant
Serous IV 3664 3254 -410 (11) 27.2 25.1 -2.1 (8)
Serous III 6857 6239 -618 (9) 21.9 18.8 -3.1 (14)
Serous III 5603 4310 -1293 (23) > 64.0 > 64.0 - (-)
Serous II 5914 5374 -540 (9) 37.9 35.4 -2.5 (7)
Mucinous 324 282 -42 (13) < 2.0 < 2.0 - (-)
Endometrioid 28.9 24.5 -4.4 (15) < 2.0 < 2.0 - (-)
Undifferentiated III 5487 5068 -419 (8) 8.8 8.1 -0.7 (8)
Benign
Simple cyst - 9.8 7.4 -2.4 (24) < 2.0 < 2.0 - (-)
Simple cyst - 8.7 7.1 -1.6 (18) 4.4 2.2 -2.2 (50)
Simple cyst - 12.4 10.3 -2.1 (17) < 2.0 < 2.0 - (-)
Simple cyst - 3.4 2.1 -1.3 (38) < 2.0 < 2.0 - (-)
Simple cyst - 7.5 6.3 -1.2 (16) < 2.0 < 2.0 - (-)
Dermoid cyst - 8.5 6.5 -2.0 (24) < 2.0 <2.0 - (-)
Dermoid cyst - 7.0 6.8 -0.2 (3) < 2.0 < 2.0 - (-)
Dermoid cyst - 14.1 13.5 -0.6 (4) 5.7 4.8 -0.9 (16)
Endometrial cyst - 27.8 27.8 0.0 (0) <2.0 < 2.0 - (-)
Endometrial cyst - 13.7 10.3 -3.4 (25) 2.6 < 2.0 ->0.6 (>23)
Endometrial cyst - 186.3 178.9 -7.4 (4) < 2.0 < 2.0 - (-)
Cystadenoma - 7.2 5.4 -1.8 (25) <2.0 <2.0 - (-)
Cystadenoma - 6.9 4.6 -2.3 (33) < 2.0 < 2.0 - (-)
Cystademona - 9.3 8.6 -0.7 (8) 2.8 2.7 -0.1 (4)
Fibroma - 23.8 11.8 -12.0 (50) < 2.0 < 2.0 - (-)
Thecoma - 56.9 51.1 -5.8 (10) 2.1 < 2.0 ->0.1 (>5)
Hydrosalpinx - 11.7 9.5 -2.2 (19) < 2.0 < 2.0 - (-)
Wilcoxon's matched pair test, ap < 0.0001. bp= 0.0077. Detection limit of CASA, 2.0-64.0 U ml-'.
From a theoretical point of view we expected a release of CA
125 and CASA from the tumours as a result of the manipulation.
However, we observed a small but statistically significant decrease
in CA 125 and CASA levels after manipulation of the pelvic
masses.
The results are not likely to be explained by analytical proce-
dures or within-day variations. The serum samples were analysed
blindly in pairs and the two samples were drawn at an interval of
approximately 24 h. The patients fasted and had had no intra-
venous fluids before the second sample was drawn, therefore
haemodilution did not occur.
In conclusion, the present study demonstrated a decrease in the
serum levels of CA 125 and CASA after a gynaecological exami-
nation combined with sonography. So far, this decline cannot be
explained, but the time of sampling should be taken into consider-
ation to avoid misclassification of the patient.
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